Seite - 108 - in Cancer Nanotheranostics - What Have We Learnd So Far?
Bild der Seite - 108 -
Text der Seite - 108 -
Alcantaraet al. Molecular imagingofbreast cancer
FIGURE1 |Microcalcifications inbreastmammography.Highly
suggestiveofmalignancyBIRADS5.
homogenize the diagnosis and injury treatmentmethods in all
centers.
BIRADSCLASSIFICATION
Category0: Additional imaging evaluation and/or comparison
topriormammograms isneeded.
Category1: Negative.
Category2: Benign(non-cancerous)finding.
Category3: Probablybenignfinding–Follow-upinashort time
frameis suggested.
Category4: Suspicious abnormality –Biopsy shouldbe consid-
ered:
Category4A:Findingwitha lowsuspicionofbeing
cancer.
Category 4B: Finding with an intermediate suspi-
cionofbeingcancer.
Category4C:Findingofmoderateconcernofbeing
cancer,butnotashighasCategory5.
Category5: Highly suggestive of malignancy – Appropriate
actionshouldbetaken.
Category6: Known biopsy-proven malignancy – Appropriate
actionshouldbetaken.
The main diagnosis and monitoring techniques of breast dis-
ease includemammography,ultrasoundandmagnetic resonance
imaging(MRI).
MAMMOGRAPHY
Mammographyis themostcommonlyusedmethodforthemon-
itoring and diagnosis of breast disease. In recent years, digital mammography has been developed, which requires lower doses
of radiation as compared to a conventionalmammography, and
alsoallows thepost-processingof images.
Mammographyisalsousedtoguideinterventionalbreasttech-
niques, suchas stereotacticmammography.Twomammographic
views, cranio-caudal andobliquemediumlateral areusuallyper-
formed and complementedwith other projections according to
needs. This technique has high sensitivity for the diagnosis of
microcalcifications. It is also used for breast screening, allowing
thedetectionofbreast lesionsataveryearlystage,whichincreases
considerably the life expectancy of affected patients. According
to the screeningprogram,amammography isusuallyperformed
every two years (two projections) in women over the age of 40
or 50,with double readby twodifferent radiologists (Houssami
etal., 2009).
However,mammographystillpresentsomedrawbacks.Firstly,
it is an ionizing technique, and although the radiation dose has
considerably decreased, it is still relevant ifwe take into account
that the breast is a radiosensitive tissue. Secondly, mammogra-
phy cannot differentiate between liquid lesions, including cysts,
and solid lesions, which is a major limitation for the accurate
identificationof tumormasses.
Two innovative techniques are included within
mammography:
Contrast-enhancedmammography
Contrastmammography, aswell asMRI, allowsdynamic vascu-
lar studies to beperformed. Several parameters canbe extracted
fromtheenhancementcurvethatprovideusefuldiagnostic infor-
mation, such as the slope and the time to peak. Thus, lesions
withearlyandintenseenhancementaresuggestiveofmalignancy
(Fallenbergetal., 2014).
This type of study has been satisfactorily used for the anal-
ysis of inconclusive lesions, the detection of occult lesions, the
monitoring of disease progression and to assess chemotherapy
response(Dromainetal., 2009).
Tomosynthesis
Tomosynthesis techniques allow us to carry out three-
dimensional breast studies. It consists of a mammography
device that uses a rotaryhead tube, performingdifferent projec-
tions of a static breast with a specified angle (between 15◦ and
45◦). It can be considered a tomographic application of digital
mammography.Tomosynthesishas evenbeenproposedasanew
screening method (Waldherr et al., 2013). Tomosynthesis has
demonstrated superior accuracy compared tomammography in
tumormeasurements and reduced the suspicious presentations
of normal tissues and tissue overlap, and facilitated accurate
differentiation of lesion types (Fornvik et al., 2010; Alakhras
etal., 2013).
ULTRASOUND
Ultrasound complements mammography, being a required
method for themanagement and diagnosis of breast pathology
(Figure2).Because itdoesnotuse ionizingradiation,ultrasound
isnotonly thefirstdiagnostic tool inyoungwomenwhohave lit-
tle riskofbreast cancer, but also thefirst diagnostic technique in
Frontiers inChemistry | ChemicalEngineering December2014 |Volume2 |Article112 | 108
Cancer Nanotheranostics
What Have We Learnd So Far?
- Titel
- Cancer Nanotheranostics
- Untertitel
- What Have We Learnd So Far?
- Autoren
- João Conde
- Pedro Viana Baptista
- Jesús M. De La Fuente
- Furong Tian
- Herausgeber
- Frontiers in Chemistry
- Datum
- 2016
- Sprache
- englisch
- Lizenz
- CC BY 4.0
- ISBN
- 978-2-88919-776-7
- Abmessungen
- 21.0 x 27.7 cm
- Seiten
- 132
- Schlagwörter
- Nanomedicine, Nanoparticles, nanomaterials, Cancer, heranostics, Immunotherapy, bioimaging, Drug delivery, Gene Therapy, Phototherapy
- Kategorien
- Naturwissenschaften Chemie